Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...
3d
A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...
According to Benzinga Pro, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 10.61%, which means the company has more short interest than most of its peers. Did ...
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Piper Sandler raised the firm’s price target on Halozyme (HALO) to $52 from $51 and keeps a Neutral rating on the shares. The firm notes ...
On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $57.15 which represents a slight increase of $6.58 or 13.01% from the prior close of $50.57. The stock opened ...
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...
Halozyme Therapeutics ( (HALO) ) has released its Q3 earnings. Here is a breakdown of the information Halozyme Therapeutics presented to its ...
As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...
Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback